Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 85%
filed 2026-06-16
EX-99.1
Aya Gold & Silver announces its inclusion in the VanEck Gold Miners ETF (GDX), effective June 19, 2026, following the ETF's quarterly rebalance. The company's CEO states this is "a significant corporate milestone" that will "enhance the liquidity and visibility of our shares while increasing awareness among a broader global investor base." This is a material operational/strategic milestone reflecting market recognition and improved capital-market access, though it does not fit the specific categories of M&A, earnings, executive changes, or financial obligations.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-15
EX-99.1
The exhibit announces a regulatory order from Puerto Rico's Energy Bureau (PREB) requiring Greenbriar and PREPA to complete negotiations on a 40 MW battery storage system contract within seven days, with specific pricing terms ($24,000–$33,000 per MW per month) and a warning of potential fines for non-compliance. This is a material operational and contractual milestone for a renewable-energy developer, but does not fit the discrete event categories (not M&A, not a financing, not a restatement, not an executive change). The regulatory directive and negotiation deadline represent a significant business development that would affect investor assessment of the company's Puerto Rico renewable-energy strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-15
EX-99.1
This press release announces Bitzero's first week of trading on Nasdaq and highlights significant operational and commercial milestones: a binding letter agreement with OneQode for a ~US$2.6 billion, 15-year lease of its 110MW Norway data center (with ~85% expected net operating income margin), advanced construction progress in Norway, and completion of engineering due diligence for its Finland campus supporting up to 520MW capacity. While the OneQode lease is binding, a definitive agreement has not been executed and remains subject to customary conditions, preventing classification as a completed M&A transaction. The disclosure is primarily operational—highlighting infrastructure development, construction milestones, and customer engagement—rather than a discrete financial event, making operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
EX-99.1
Belite Bio announced completion of a rolling New Drug Application (NDA) submission to the FDA for tinlarebant for Stargardt disease type 1, a rare inherited retinal disease with no approved treatments. The submission was made under Breakthrough Therapy Designation and represents a significant regulatory milestone for a clinical-stage company. While this is a material operational/regulatory event affecting the company's drug development pipeline and commercial prospects, it does not fit the specific event types (e.g., earnings_release, exec_departure, ma_activity) and is best classified as an operational milestone in the drug development process.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
EX-99.1
This news release announces Fortuna's receipt of an environmental decree from Senegal's Ministry of Environment approving the Environmental and Social Impact Assessment for the Diamba Sud Gold Project. This is a material operational and regulatory milestone—a key permitting approval that advances the project toward mining permit and final construction decision (targeted mid-2026). While not a discrete M&A event, executive change, or financial restatement, it represents a significant operational achievement that would affect a reasonable investor's assessment of the company's ability to develop this project. The disclosure emphasizes the project's robust economics (72% after-tax IRR, US$563M NPV) and the company's progress toward major milestones, making it material to the registrant's strategic development pipeline.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-15
EX-99.1
The press release discloses a U.S. Department of Energy order mandating that TransAlta's Centralia Unit 2 remain available for operation for an additional 90 days through September 13, 2026. This is a regulatory directive affecting the operational status of a material asset. While not fitting a discrete named event type (not M&A, not a workforce reduction, not litigation), it is clearly an operational/regulatory matter that would affect investor assessment of the company's generation capacity and compliance obligations. The materiality stems from the operational constraint imposed on a significant power generation facility.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-15
EX-99.1
This press release announces a key operational milestone: receipt of the first custom-built underground haul truck from Young's Machine Company and a new equipment supply agreement. The disclosure demonstrates material progress toward production at Anfield's uranium-vanadium mines (Velvet-Wood, JD-8, Slick Rock) and reflects the company's advancement of its hub-and-spoke production model. While not a discrete M&A transaction, debt issuance, or financial result, this operational achievement—securing critical mining equipment and establishing a supply partnership—would affect a reasonable investor's assessment of the company's ability to execute its development strategy and timeline.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
EX-99.1
Legend Biotech announced clinical proof-of-concept data for LB2501, an investigational in vivo CAR-T therapy, presented at EHA 2026. Phase 1 trial results demonstrated 100% ORR and 83.3% CR at dose level 2 with a favorable safety profile, no dose-limiting toxicities, and supporting pharmacokinetic/integration data for the TaVec platform.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
Tower Semiconductor and IQE announced a multi-year supply agreement for Indium Phosphide epiwafers supporting Tower's silicon photonics platforms for AI-driven data center infrastructure, with minimum purchase and volume commitments. The agreement also resolves all prior IP disputes through a royalty-free patent license. This is a material strategic partnership and supply arrangement affecting Tower's product roadmap and competitive positioning in high-growth optical connectivity markets, but does not fit the specific categories of M&A, debt, equity issuance, or other defined event types.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-15
The 6-K discloses Week 182 data from the completed Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide), demonstrating sustained efficacy and safety in hypoparathyroidism over three-and-a-half years. This is a material clinical milestone—positive Phase 3 trial results supporting regulatory approval and commercial viability—but does not fit the discrete event categories (not an earnings release, M&A activity, executive change, or financial obligation). It is a material operational/clinical development that would affect investor assessment of the product's regulatory and commercial prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
EX-99.1
This press release announces a strategic partnership between OwlTing Group and Credible Finance to open cross-border payment corridors, starting with China and planned expansion to India. The disclosure highlights material operational developments: OwlPay Harbor enterprise clients have grown to 51 (up 40% since full-year 2025 results), transaction orders have doubled monthly with 103% compound monthly growth rate, and the partnership is designed to expand global payout capabilities and market reach. While not a discrete M&A transaction, this network-to-network partnership represents a significant operational and strategic milestone for the Company's payment infrastructure business.
View raw filing on EDGAR →
6-K
Operational Other
confidence 82%
filed 2026-06-15
EX-99.1
Ascentage Pharma disclosed seventeen clinical updates from its core assets—olverembatinib (HQP1351) and lisaftoclax (APG-2575)—presented at the EHA2026 Congress, including efficacy and safety data from multiple Phase II and Phase III studies across hematologic malignancies. Key highlights include Phase III POLARIS-1 data showing 94.4% CR/CRi rate in Ph+ ALL and Phase II data supporting olverembatinib as second-line therapy in CML, representing material progress toward regulatory approval and commercial potential.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
EX-99.1
This press release announces a key human performance and characterization study for NASARIX™ (PL-14), Polyrizon's lead investigational product, conducted in collaboration with a leading European university medical center. The study is designed to evaluate nasal residence time—a critical performance parameter supporting the company's FDA regulatory pathway and development strategy. For a development-stage biotech company, advancement of a lead product through human studies and regulatory milestones is material to investor assessment of progress and value.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-15
EX-99.1
This news release discloses an updated NI 43-101 Technical Report for Silvercorp's Ying Mining District showing a 50% increase in mineral reserve tonnes and 20% increase in silver ounces, along with updated mineral resource estimates and a 17-year life-of-mine production profile with projected NPVs of $1,275M (pre-tax) and $1,030M (post-tax). While the document contains technical and financial projections, it is fundamentally an operational disclosure of updated mineral reserve and resource estimates—a material update to the company's asset base and production potential that would affect a reasonable investor's assessment of the registrant's long-term value and operational capacity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-15
EX-99.1
Ecopetrol announces a final collective bargaining agreement with the Oil Workers Union (USO) and 66 other labor unions, effective January 1, 2026, following over 990 negotiation sessions. The agreement includes improvements in working conditions, health and education benefits, diversity initiatives, and social investment. This is a material operational and labor-relations event affecting a major integrated energy company with 19,000+ employees, as it resolves a significant labor negotiation and establishes terms for a six-year period, but does not fit the specific categories of workforce reduction, exec compensation, or governance matters.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
EX-99.1
Cuprina announced receipt of U.S. FDA 510(k) clearance for MEDIFLY Maggots, a medical-grade Lucilia cuprina larvae product for maggot debridement therapy. This is a significant regulatory milestone and product approval that enables commercial launch in the U.S. market. While not a discrete M&A, financing, or governance event, this regulatory clearance is a material operational and strategic achievement that would affect a reasonable investor's assessment of the company's product portfolio and market opportunities, particularly as it positions Cuprina as the only company holding FDA clearance for both maggot species used in MDT.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
EX-99.1
Dr. Reddy's announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States on June 13, 2026. This is a material product launch in the oncology segment with 180-day generic drug exclusivity, targeting a market with approximately $253.8 million in annual sales for the branded equivalent. The disclosure is a strategic operational milestone—a new product commercialization—rather than a discrete financial event (earnings, debt, M&A) or governance matter, making it operational_other.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
This 6-K discloses FDA approval of Truqap (capivasertib) in combination with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer, based on positive Phase III CAPItello-281 trial results showing a 19% reduction in risk of disease progression or death. This is a material regulatory milestone and product approval event that expands AstraZeneca's oncology portfolio into a second tumor type, representing a significant operational and commercial development rather than a discrete financial, governance, or legal event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
EX-99.2
This press release announces FDA approval of Obagi® saypha® ChIQ™, a new injectable hyaluronic acid gel product for the Obagi Medical brand (owned by Waldencast). The approval expands Obagi's injectable portfolio and strengthens its position in the dermal filler market. This is a material operational/product milestone—a regulatory approval that materially expands the company's addressable market in the fast-growing U.S. dermal filler category and advances its strategy to establish Obagi as a comprehensive leader in medical aesthetics. While not a discrete M&A, litigation, or financial event, the approval of a new product with significant market potential is material to investors assessing the company's growth trajectory and competitive positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
EX-99.1
DHT Holdings announced entry into an agreement with Hanwha Ocean for construction of a new VLCC vessel scheduled for delivery in August 2028, representing a material capital deployment and fleet expansion decision financed through cash flow, liquidity, and projected mortgage debt.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-12
EX-99.1
Austin Gold has filed a National Instrument 43-101 technical report on its Stockade Mountain Project documenting exploration activities, drilling results (including significant gold grades of 8.19 g/t and 9.32 g/t), and identifying new untested drill targets based on geophysical surveys. This material operational disclosure advances the company's core business objective of making district-scale gold discoveries and demonstrates progress on its primary asset.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-12
The 6-K discloses positive Phase 2 clinical trial results for TransCon PTH (palopegteriparatide) in hypoparathyroidism, announced June 11, 2026. The five-year PaTH Forward Trial data demonstrates sustained efficacy and safety with high responder rates (82%), maintained kidney function improvements, and quality-of-life benefits. This is a material clinical milestone for a biopharmaceutical company's lead program, but it is not a discrete event type in the taxonomy (not earnings, M&A, litigation, or other named categories). It is clearly operational—a significant product development and regulatory milestone—making `operational_other` the best fit.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
EX-99.2
The European Commission approved Sarclisa (isatuximab) subcutaneous formulation administered via an on-body injector for multiple myeloma treatment. This regulatory approval expands the commercial availability and delivery method of the existing marketed drug, representing a material operational and commercial development for Sanofi's oncology portfolio.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-12
EX-99.3
Sanofi terminated the MOBILIZE phase 3 clinical trial of riliprubart in CIDP patients following an interim analysis showing insufficient efficacy. The failure of the phase 3 study represents a material setback to the company's pipeline and R&D direction, affecting investor assessment of future revenue potential.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
EX-99.1
Hydro One announced filing a leave-to-construct application with the Ontario Energy Board for the Durham Kawartha Power Line, a ~$430 million transmission infrastructure investment project expected to be in service in 2029. This is a material operational and strategic business event—a major capital project milestone involving regulatory approval—that does not fit a specific named category. The scale ($430M investment), strategic importance to grid reliability and growth support, and First Nations partnership equity component make this material to investors assessing the company's capital deployment and operational strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
EX-99.1
Hydro One announced filing a leave-to-construct application with the Ontario Energy Board for the Durham Kawartha Power Line, a ~$430 million transmission infrastructure investment project expected to be in service in 2029. This is a material operational and strategic business event—a major capital project announcement involving regulatory approval—that does not fit a specific named category. The scale ($430M investment), strategic importance (grid reliability and growth support), and First Nations partnership model make this material to investors assessing the company's capital deployment and operational strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
EX-99.1
Park Ha Biological announced a comprehensive strategic partnership with Star Plus Action (subsidiary of Star Plus Legend Holdings) to build an AI-powered skincare and health ecosystem. The disclosure describes joint development of AI-powered products (AI Nutritionist, AI store managers, AI skincare specialists), resource integration across healthcare, skincare, IP management, and AI technology, and plans for full-chain intelligent service deployment. This is a material operational and strategic business event—a significant partnership and business model expansion—that does not fit the specific categories of M&A activity (no acquisition/merger/change of control), debt issuance, or other named types. It represents a transformative strategic collaboration affecting the company's business direction and competitive positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
GSK announced that momelotinib received Orphan Drug Designations (ODD) from the FDA and EMA for VEXAS syndrome treatment, with a planned phase II/III ATLAS trial underway. This is a material regulatory milestone for a rare disease indication that would affect investor assessment of the company's pipeline and development strategy, but it does not fit the specific event categories (not an earnings release, M&A activity, executive change, debt issuance, or other named types). The ODD designation and trial advancement represent a significant operational/strategic development in the drug's regulatory pathway.
View raw filing on EDGAR →